Epoch Biosciences, of Bothell, Wash., has appointed Walt Mahoney as senior vice president for Research and Development. Mahoney most recently served a short stint as chief scientific officer at Quantum Dot of Hayward, Calif., which makes quantum dot-labeled beads for DNA arrays and numerous other purposes.
Before joining Quantum Dot last April, Mahoney headed up Roche’s US chief technology office. He also served as director of discovery research at Boehringer Mannheim and has worked at at Biotope, Sanofi, and ImmunoNuclear, in addition to serving as professor of genetics and cell biology at the University of Minnesota.
PharmaSeq, a Monmouth, NJ startup with DNA arrays that consist of miniature radio-transponders with oligonucleotides attached, has hired Richard Morris as Chief Executive Officer. Wlodek Mandecki, the microtransponder’s inventor and founder of the company, will serve as president of PharmaSeq.
Morris joins PharmaSeq from CambridgeSoft, a Cambridge, Mass. life sciences software company, where he served as chief marketing officer and president of e-commerce. Previously, Morris has held sales management positions at Sigma-Aldrich research in St. Louis and at Molecular Dynamics; and worked as vice president of International Operations at Durrum Instruments, (Now Dionex) in Sunnyvale, Calif.
BioMicro Systems, a Sandy, Utah microfluidics startup, has hired Scott Romney as its inaugural director of marketing. Romney joins the company from Northwest Drug Testing, a division of Salt Lake City-based drug testing lab NWT, where he began working in 1999. He also worked for 13 years as the marketing manager for toxicology at ARUP Laboratories.
BioMicro is seeking to commercialize microfluidics technology that has the mechanism of passive fluid control for genomics, diagnostics, drug development, and other life science research. The company just introduced a Microarray User Interface (MAUI), a microfluidics-based hybridization chamber into which a user can place a slide. The idea underlying MAUI is to automate fluid delivery and hybridization in order to minimize user error in performing microarray experiments. The company plans to release commercial-scale MAUI devices that can handle up to 20 slides at once.